

AGENDA

*Uniform Formulary Beneficiary Advisory Panel
5 April 2012 @ 0900 AM*

*Naval Heritage Center Theater
701 Pennsylvania Ave. NW., Washington DC 20004*

- **Administrative Meeting (BAP members only @ 8:00 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations of the following drug classes during the Feb 2012 meeting:

- *Drug Class Reviews:*
 - *Antiplatelet Agents*
 - *Dipeptidyl Peptidase-4 (DPP-4) Inhibitors*
 - *Attention Deficit Disorder Hyperactivity Disorder (ADHD)/Wakefulness Promoting Agents*
- *Designated Newly Approved Drugs:*
 - *Ophthalmic-1 Class—Alcaftadine ophthalmic solution (Lastacft)*
 - *Narcotic Analgesics—Tapentadol extended release tablets (Nucynta ER)*
- *Utilization Management:*
 - *Crizotinib (Xalkori) for non-small cell lung cancer Prior Authorization*
 - *Vermurafenib (Zelboraf) for metastatic melanoma Prior Authorization*
 - *Ivacaftor (Kalydeco) for cystic fibrosis Prior Authorization*
- **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any

questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.